Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS

Mansour, Asieh; Samadi, Majid; Sanginabadi, Milad; Gerami, Hadis; Karimi, Sara; Hosseini, Saeed; Shirzad, Nooshin; Hekmatdoost, Azita; Mahdavi-Gorabi, Armita; Mohajeri-Tehrani, Mohammad Reza; Qorbani, Mostafa

doi:10.1016/j.clnu.2021.02.004

Cited by 30 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with the above types of surgery tend to be older, and most of them need to take antiplatelet agents ( 6 – 8 ). Some common diseases in endocrinology can also be affected by antiplatelet drugs ( 9 – 11 ).…”

Section: Introductionmentioning

confidence: 99%

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES

Wang

Zhu

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundOsteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.MethodsData in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regressionResultsAfter excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05).ConclusionThis study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES

Wang

Zhu

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…However, the high‐quality oocyte rate and high‐quality embryo rate were higher in the resveratrol group ( p = 0.002 and p = 0.024, respectively). Mansour et al 21 reported that supplementation with 1000 mg/day resveratrol for 3 months did not significantly change dehydroepiandrosterone (DHEA), sex hormone‐binding globulin (SHBG), LH, FSH and ovarian and adrenal androgens loss, glycoinsulinaemic metabolism and body weight ( p > 0.05) in PCOS patients. Another study by Banaszewska et al 37 demonstrated that resveratrol supplementation at a dosage of 1500 mg/day led to a 23.1% decrease in total testosterone level ( p = 0.01) and a 22.2% decrease of DHEA sulphate concentration ( p = 0.01), indicating an effect on ovarian as well as adrenal androgen production.…”

Section: Resultsmentioning

confidence: 99%

“…However, the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (p = 0.002 and p = 0.024, respectively). Mansour et al 21…”

Section: The Effects Of Resveratrol On Reproductive Hormones In Pcosmentioning

confidence: 99%

The therapeutic effects and mechanisms of action of resveratrol on polycystic ovary syndrome: A comprehensive systematic review of clinical, animal and in vitro studies

Karimi

Tutunchi

Naeini

et al. 2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most important and common polygenic endocrine disorders among women of reproductive age. Resveratrol, a natural phenol, is involved in various biological activities, including antioxidant, antiseptic, anti‐inflammatory, anti‐ageing and anti‐cancer effects. This systematic review aimed to investigate the therapeutic effects and mechanisms of actions of resveratrol in PCOS. The present study was conducted according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta‐Analysis statements. We searched PubMed, Science Direct, Google Scholar, Scopus, ISI Web of Science, ProQuest and Embase databases up to August 2021 by using the relative keywords. Original studies published in the English language that assessed the effects of resveratrol on PCOS and its associated complications were considered. Out of 417 records screened, only 24 articles met the inclusion criteria: 10 in vitro, 10 animal and 4 human studies. The results obtained in the present study showed that resveratrol supplementation might be effective in improving PCOS‐related symptoms by reducing insulin resistance, alleviating dyslipidaemia, improving ovarian morphology and anthropometric indices, regulating the reproductive hormones and reducing inflammation and oxidative stress by affecting biological pathways. According to the available evidence, resveratrol may reduce the complications of PCOS. However, further studies are recommended for a comprehensive conclusion on the exact mechanism of resveratrol in PCOS patients.

show abstract

“…The clinical data described on reversing insulin resistance have been variable. In the study conducted by Mansour et al [22], when human subjects were given resveratrol at 1000 mg, daily, for 3 months compared to a placebo, the resveratrol treatment group did not have significantly reduced adiposity. Furthermore, the study did not note a significant difference in insulin level, fasting blood glucose level, nor the HOMA-IR (insulin resistance index) between the two groups after 3 months.…”

Section: Metabolic Markers and Insulin Resistancementioning

confidence: 91%

“…These results suggest that combined therapy of resveratrol and metformin has the most potential to improve weight gain and the hormone profile in PCOS patients, and to reduce inflammatory damage via SIRT1 and MAPK activation. Mansour et al [22], conducted a randomized study on PCOS women ages 18-40 receiving either 1000 mg of resveratrol or 1000 mg of the placebo, daily, for a period of 3 months. The placebo and resveratrol treatment groups had no difference in adrenal and ovarian androgens or androgen index, but the resveratrol treatment group did show improvement in menstruation rates and reduced hair loss.…”

Section: Pcos Markers Including Hormonesmentioning

confidence: 99%

Effects of Resveratrol on Metabolic, Biochemical, and Endocrine Manifestations in Polycystic Ovary Syndrome

2022

View full text Add to dashboard Cite

Polycystic Ovary Syndrome (PCOS) is a reproductive, hormonal, and metabolic disorder frequently associated with insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress. Resveratrol is a naturally occurring polyphenolic stilbene found in trace amounts in some food items. It has been extensively used as a treatment option for metabolic disorders but its use in PCOS treatment has been limited. This review emphasizes the effect of resveratrol on the clinical features of PCOS, ovarian morphology, androgen profile, markers of oxidative stress, inflammatory markers, and metabolic markers associated with PCOS.

show abstract

Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS

Cited by 30 publications

References 23 publications

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES

Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES

The therapeutic effects and mechanisms of action of resveratrol on polycystic ovary syndrome: A comprehensive systematic review of clinical, animal and in vitro studies

Effects of Resveratrol on Metabolic, Biochemical, and Endocrine Manifestations in Polycystic Ovary Syndrome

Contact Info

Product

Resources

About